Inma Hernandez, Sean Sullivan, and Emma Cousin predict that as many as six oral cancer drugs could be selected for Medicare price negotiation in the next round, which begins in 2024 for prices going into effect in 2027. A number of diabetes drugs may also be targeted, including Novo Nordisk’s Ozempic. According to these policy experts, 13 drugs can be identified as eligible for negotiation. Five more can be identified as potentially eligible, but for which there is less certainty because of possible changes in Medicare spending trends.
Findings were presented at an ISPOR the webinar IRA Part II: Next 15 for Medicare Drug Price Negotiations in 2025 on July 11. For those who missed the webinar, the full list, with rationale, in the July 16, 2024 edition of the Pink Sheet